期刊
SCIENCE SIGNALING
卷 11, 期 511, 页码 -出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scisignal.aan0790
关键词
-
资金
- NIH, NCI, Center for Cancer Research
- Department of Science and Technology, Guizhou Province [G[2014]7020, J[2015]2003]
- University of Macau [SRG2014-00024-ICMS-QRCM, MYRG2016-00023-ICMS-QRCM, MYRG2017-00120-ICMS]
- Science and Technology Development Fund of Macao SAR (FDCT) [014/2015/A1]
Through the tumor necrosis factor (TNF) receptor type II (TNFR2), TNF preferentially activates, expands, and promotes the phenotypic stability of CD4(+)Foxp3(+) regulatory T (T-reg) cells. Those T-reg cells that have a high abundance of TNFR2 have the maximal immunosuppressive capacity. We investigated whether targeting TNFR2 could effectively suppress the activity of T-reg cells and consequently enhance the efficacy of cancer immunotherapy. We found that, relative to a suboptimal dose of the immunostimulatory Toll-like receptor 9 ligand CpG oligodeoxynucleotide (ODN), the combination of the suboptimal dose of CpG ODN with the TNFR2-blocking antibody M861 more markedly inhibited the growth of subcutaneously grafted mouse CT26 colon tumor cells. This resulted in markedly fewer TNFR2(+) T-reg cells and more interferon-gamma-positive (IFN-gamma(+)) CD8(+) cytotoxic T lymphocytes infiltrating the tumor and improved long-term tumor-free survival in the mouse cohort. Tumor-free mice were resistant to rechallenge by the same but not unrelated (4T1 breast cancer) cells. Treatment with the combination of TNFR2-blocking antibody and a CD25-targeted antibody also resulted in enhanced inhibition of tumor growth in a syngeneic 4T1 mouse model of breast cancer. Thus, the combination of a TNFR2 inhibitor and an immunotherapeutic stimulant may represent a more effective treatment strategy for various cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据